Treatment of childhood acute lymphoblastic leukaemia: present issues and future prospects

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Research

Background:

• Modern acute lymphoblastic leukaemia (ALL) treatment achieves long-term survival in approximately two-thirds of pediatric patients.
• Recent advancements stem from intensified treatment protocols, particularly in the initial six months post-diagnosis.

Purpose of the Study:

• To review methods for identifying children requiring non-standard therapy for ALL.
• To discuss aspects of standard ALL therapy needing refinement, including central nervous system (CNS) directed treatment and maintenance therapy.
• To explore the potential of minimal residual disease (MRD) identification for treatment stratification and relapse risk assessment.

Main Methods:

• Review of current treatment strategies for pediatric ALL.
• Analysis of methods for identifying patients for alternative therapies like bone marrow transplantation.
• Discussion of challenges in treating relapsed ALL and managing long-term side effects.

Main Results:

• Intensified early treatment has improved survival rates in childhood ALL.
• Minimal residual disease (MRD) detection offers promise for personalized treatment approaches.
• Treatment for relapsed ALL remains challenging, often associated with significant morbidity.

Conclusions:

• Despite progress, refining ALL treatment to minimize late effects and improve outcomes for relapsed patients is crucial.
• Further studies are needed for optimal patient selection for alternative therapies, such as bone marrow transplantation.
• Ongoing research aims to develop more effective ALL treatments with reduced long-term toxicity.